EGFR and non-small cell lung carcinoma: The phase I CHRYSALIS trial examined the bispecific antibody, amivantamab, for advanced NSCLC with EGFR exon20 insertion mutation, and demonstrated a 40% response rate and a progression-free survival of 8.3 months, resulting in a breakthrough therapy designation [75].